Oncolytic virus treatment for early bladder cancer that keeps coming back
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an “oncolytic virus” treatment given into the bladder to fight high-grade non–muscle-invasive bladder cancer. It may help people whose bladder cancer did not respond to initial bladder prevention treatments, potentially delaying or avoiding major bladder surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 80 years old, and you can be male or female.
- Your bladder cancer is early stage (Ta, T1, or Tis) and “high grade,” and it’s not muscle-invasive or spread.
- You tried the first preventive bladder treatment (bladder perfusion) and it failed, and your bladder can still be kept.
- You had a recent bladder procedure (TURBT) and your follow-up bladder tissue and urine tests did not show active cancer in those samples.
- You don’t have cancer in the upper urinary tract, and you haven’t had chemotherapy or radiation for bladder cancer before starting this study.
- You can do treatment safely: good performance status, enough blood counts, acceptable kidney/liver tests, and no active fever/infection at the start.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
This trial tests a new treatment called HIVEC (a type of heated chemotherapy placed directly into the bladder) for people with non-muscle-invasive bladder cancer that is at medium or high risk of coming back. It aims to see if this approach can reduce the chance of cancer returning.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new type of virus therapy that is put directly into the bladder for people with high-risk bladder cancer that hasn't spread into the muscle. The goal is to see if it is safe and effective at keeping the cancer from coming back.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.